IDEOM

International Dermatology Outcome Measures is a non-profit organization seeking to develop and validate measures throughout dermatology.

[IDEOM @Dermoutcomes]

Measuring treatment satisfaction helps capture an important part of the patient experience in derm. DermSat-7 is a free-to-use, 7-item patient-reported instrument developed for dermatologic conditions & validated in psoriasis & acne.

Access: [email protected]

#Dermatology

[IDEOM @Dermoutcomes]

DEOM will be at Lisbon @GrappaO 2026 🇵🇹
If you’re attending GRAPPA, we’d love to see you at our open IDEOM gathering to connect and advance patient-centered outcomes work together. Find us there!

#GRAPPA #GRAPPA26 #IDEOM #Dermatology

[IDEOM @Dermoutcomes]

Psoriatic disease goes beyond the skin. MSK-Q is a free, validated patient-reported questionnaire capturing MSK symptom burden in psoriasis/PsA: symptom intensity, daily life impact, and fatigue. Validated in 1,453 patients.

Request access: [email protected]

#PsA #IDEOM

[IDEOM @Dermoutcomes]

Free, validated PRO instruments for dermatologic research. IDEOM MSK-Q measures musculoskeletal symptoms and their impact in psoriatic disease. DermSat-7 captures treatment satisfaction across skin conditions.

Request access today!

#Dermatology #ClinicalResearch #Psoriasis

[IDEOM @Dermoutcomes]

One room. Physicians, patients, researchers, payers, caregivers, nurses & more- all working toward the same goal: evidence-based outcomes measures that actually reflect what matters to patients. Grateful for this community. Here's to another year of progress.
#IDEOM #Dermatology

[IDEOM @Dermoutcomes]

As we look ahead to our 13th Annual this June, we’re reflecting on progress from last year. The CTCL Workgroup identified 19 candidate health-related quality-of-life concepts through two Delphi rounds for clinical trials in mycosis fungoides and Sézary syndrome.
#Dermatology

[IDEOM @Dermoutcomes]

Deadline extended to May 15! 📣

Submit your outcomes research abstract for the #IDEOM2026 Annual Meeting (June 19–20, DC). Open to patients, clinicians, trainees & industry — no fee for IDEOM stakeholders.

Submit → https://t.co/3WRdT7rtk3

#DermOutcomes #DermatologyResearch

[IDEOM @Dermoutcomes]

HS affects more than the skin. At last year's meeting, the HS Workgroup advanced validation of the IDEOM MSK-Q, a tool designed to capture musculoskeletal pain, joint swelling, joint stiffness, fatigue, & functional impact in people living with hidradenitis suppurativa.
#HS

[IDEOM @Dermoutcomes]

Congratulations to our President, Dr. Alice Gottlieb MD, PhD, on her appointment as VP of the @AADermAssoc! 🎉
Her leadership, vision, and unwavering commitment to patients and the dermatology community make this honor so well deserved. We are incredibly proud!
#MedicalLeadership

[IDEOM @Dermoutcomes]

Dermatology’s patient population is aging, but many QoL tools still miss what matters most to older adults. The AGED Workgroup is helping close that gap by advancing geriatric-specific outcome measures in dermatology.

#Dermatology #IDEOM

[IDEOM @Dermoutcomes]

Congrats to Dr. Jaleel on receiving the @dermfoundation – @SkinOfColor Collaborative Mid-Career Award at the 22nd Annual SOCS Scientific Symposium. We’re proud to have her as a leader in IDEOM’s HS Workgroup & celebrate this well-deserved recognition!

#Dermatology #HS

[IDEOM @Dermoutcomes]

At last year’s meeting, the Psoriatic Disease Workgroup shared progress on DermSat-11, psoriasis remission, IDEOM MSK-Q validation, and better PsA screening + management with PEST and PsAID-12.

More this June at IDEOM’s Annual Meeting!

#Psoriasis #PsA

[IDEOM @Dermoutcomes]

Up to 41% of psoriatic arthritis cases may go undiagnosed, increasing the risk of joint damage. IDEOM highlights how adding PEST + PsAID-12 to the EMR may support earlier detection and better PsA management.

https://t.co/u1fHsxDEr7

[IDEOM @Dermoutcomes]

What does meaningful progress in vitiligo research look like? At last year’s IDEOM meeting, the Vitiligo Workgroup validated key domains in the vitiligo model & used them to develop a new patient satisfaction tool focused on experiences existing measures don’t capture.
#Vitiligo

[IDEOM @Dermoutcomes]

For many patients, itch is the most disruptive part of skin disease. At IDEOM’s meeting, the Itch Workgroup highlighted growing consensus around the WI-NRS as a key measure of patient experience & discussed treating itch as a condition in its own right.
#Dermatology #Itch #IDEOM

[IDEOM @Dermoutcomes]

Evans Kojo Baffoe shares how he found IDEOM and why he’s advocating for better psoriasis awareness, support, and access to care in Ghana and across Africa.

Watch his full interview: https://t.co/FMGgrvRtzw

#Psoriasis #IDEOM

[IDEOM @Dermoutcomes]

IDEOM will be at Lisbon GRAPPA 2026 🇵🇹
If you’re attending @GrappaO , we’d love to see you at our open IDEOM gathering to connect and advance patient-centered outcomes work together. Find us there!

#GRAPPA #GRAPPA26 #IDEOM #Dermatology

[IDEOM @Dermoutcomes]

We build patient-centered outcome measures. 2024 Annual Meeting report just published: psoriatic disease work includes PEST + PsAID-12 in 26 clinics to help detect PsA earlier: https://t.co/IOEBqpOljg
#DermResearch

WG: @JosephMerolaMD, @_AprilArmstrong, Perez-Chada, & Gottlieb

[IDEOM @Dermoutcomes]

At IDEOM, we don’t just develop outcome measures, we build the ecosystem that makes them meaningful.
Patients, researchers, payers & clinicians all have a seat at the table.

And yes, our tools are always free to use!

#PatientCenteredCare #DermTwitter

[IDEOM @Dermoutcomes]

CTCL patients say “average itch” misses the point... itch flares. Measuring worst itch + sleep/function impact better reflects lived experience.

Shoutout to Jenny Park & @krithikanayudu (IDEOM CTCL Workgroup).

#CTCL #IDEOM #PatientCenteredResearch